copaydosingefficacyresourcesafety

THIS SITE IS INTENDED FOR US AUDIENCES ONLY

Oral Ulcers in Behçet's Disease

Mechanism of Action

Otezla® (apremilast) inhibits PDE4 intracellularly and has
anti-inflammatory properties1-3

Click arrow for more information

  • Mechanism of Action Diagram - PDE4
  • Mechanism of Action Diagram - Otezla

PDE4 has been shown to be present within inflammatory cells2-5

Inflammatory cella

The interior of an inflammatory cell showing how phosphodiesterase 4 (PDE4) breaks down cyclic AMP into AMP

The role of phosphodiesterase 4 (PDE4) and cyclic adenosine monophosphate (cAMP) in controlling inflammation

  • cAMP is a second messenger for a variety of inflammatory mediators4
  • PDE4 is a cAMP-specific PDE that has been shown to degrade cAMP to AMP in inflammatory cells3-5
  • The balance between cAMP and AMP within a cell may modulate the expression of pro-inflammatory and anti-inflammatory mediators2

Otezla is a non-biologic PDE4 inhibitor that works intracellularly1-3

Inflammatory cella

The mechanism of action of Otezla

  • The specific mechanism(s) by which Otezla® (apremilast) exerts its therapeutic action in patients with BD is not well defined3
  • By elevating cAMP levels, Otezla is thought to indirectly modulate production of inflammatory mediators1,2

References: 1. Schafer PH, Parton A, Gandhi AK, et al. Br J Pharmacol. 2010;159(4):842-855. 2. Schafer P. Biochem Pharmacol. 2012;83(12):1583-1590. 3. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 4. Moore AR, Willoughby DA. Clin Exp Immunol. 1995;101(3)387-389. 5. Soto FJ, Hanania NA. Curr Opin Pulm Med. 2005;11(2):1583-1590.

Indications & Important Safety Information

Please click here for Full Prescribing Information.

You are leaving the Otezla® (apremilast) website

Do you wish to leave this site?

Are You a Healthcare Professional?

.marketAccessModal .lineOne, .marketAccessModal .lineTwo { font-size: 44px; text-transform: none; margin-bottom: 10px; } .marketAccessModal .lineTwo { font-size: 42px; text-transform: none; } @media screen and (max-width: 450px) { .marketAccessModal .lineOne, .marketAccessModal .lineTwo { font-size: calc(15px + 7 * ((100vw - 325px) / 125)); } }
The FDA approves a new indication for Otezla® (apremilast) Learn more about this treatment option for your patients
EXPLORE